🔎 Trials Near Me

Home › NCT05550298

Multi-Center Molecular Diagnosis and Host Response of Respiratory Viral Infections in Pediatric Transplant Recipients

RecruitingObservational study

Who can join

Up to age 18 · All sexes

Full eligibility criteria
Recipient Inclusion Criteria

* Less than 18 years at the time of anticipated transplant
* Participant meets one of the following criteria:

  1. scheduled to receive allogeneic hematopoietic cell transplant within 14 days of enrollment or
  2. Scheduled to or received solid organ transplant within 7 days before or after enrollment
* Participant is receiving care at the time of enrollment at one of the study participating institutions.
* Parent/guardian willing and able to provide informed consent, and if appropriate, child willing and able to provide informed assent.

Donor Inclusion Criteria

* Donor for HCT recipient enrolled on the VIPER study.
* Willing and able to provide informed consent.

Exclusion Criteria:

Recipient Exclusion Criteria

None

Donor Exclusion Criteria

* Is not an HCT donor for a participant enrolled on the VIPER study.
* Not available to provide pre-transplant research blood sample.

About the study

The participants are being asked to take part in this clinical trial, a type of research study, because the participants are scheduled to receive or have recently received a hematopoietic cell transplant (HCT) or a solid organ transplant (SOT).

Primary Objective

To determine if pre-transplant screening for respiratory viral load predicts RVI within 1- year post-transplant among survivors.

Secondary Objectives:

* To develop and validate a classifier based on pre-transplant immunological profile predictive of developing an acute respiratory viral infection (aRVI), with RSV/PIV3/HMPV/SARS-CoV-2 through one-year post-transplant among survivors. * To develop and validate a classifier based on Day +100 post-transplant immunological profiles predictive of developing an acute respiratory viral infection (aRVI),with RSV/PIV3/HMPV/SARS-CoV-2 through one-year post-transplant among survivors .

Sponsor: Arkansas Children's Hospital Research Institute · Participants: 2,000 · Started: Dec 13, 2022

Contact the study team

Official record on ClinicalTrials.gov — NCT05550298

Locations in the U.S.

AlabamaUniversity of Alabama at Birmingham's (UAB), Birmingham
ArkansasArkansas Children's Hospital, Little Rock
District of ColumbiaChildren's National Medical, Washington D.C.
FloridaUniversity if Miami, Miami
GeorgiaEmory and Children's Healthcare of Atlanta, Atlanta
IllinoisUniversity of Chicago Medicine Comer Children's Hospital, Chicago
KentuckyUniversity of Louisville, Louisville
MassachusettsBoston Children's Hospital, Boston
MichiganC.S. Mott Children's Hospital, Ann Arbor
Children's Hospital of Michigan, Detroit
MinnesotaUniversity of Minnesota, Minneapolis
MissouriWashington University, St Louis
NebraskaUniversity of Nebraska Medical Center, Omaha
New YorkThe Children's Hospital at Montefiore, The Bronx
OhioCincinnati Children's Hospital Medical Center, Cincinnati
Nationwide Children's Hospital, Columbus
PennsylvaniaUPMC, Pittsburgh
South CarolinaMedical University of South Carolina, Charleston
TennesseeLe Bonheur Children's Hospital, Memphis
St. Jude Children's Research Hospital, Memphis
UT Le Bonheur, Memphis
TexasCook Children's, Fort Worth
Baylor College of Medicine, Houston
MD Anderson Center Center, Houston
UTHealth Houston, Houston
WashingtonSeattle Childrens, Seattle
WisconsinChildren's Hospital of Wisconsin, Milwaukee

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.